US Pharma MarketingThe post First patient dosed in Enanta’s Phase IIb/III trial for RSV appeared first on Clinical Trials Arena.
First patient dosed in Enanta's Phase IIb/III trial for RSV
Enanta Pharmaceuticals has dosed the first patient in its Phase IIb/III RESOLVE trial assessing zelicapavir in high-risk adult outpatients diagnosed with RSV infection. Initial results from the programme's Phase IIb segment are expected in 2027. The study is assessing zelicapavir across an adult cohort presenting with respiratory symptoms alongside a confirmed RSV diagnosis. Credit: Jarun Ontakrai / Shutterstock.com. Enanta Pharmaceuticals has dosed the first patient in its global Phase IIb/III RESOLVE trial assessing zelicapavir in high-risk adult outpatients diagnosed with respiratory syncytial virus (RSV) infection. Initial results from the Phase IIb segment of the programme are anticipated in 2027. LOA…
Enanta Pharmaceuticals has dosed the first patient in its Phase IIb/III RESOLVE trial assessing zelicapavir in high-risk adult outpatients diagnosed with RSV infection.
Source: Clinical Trials Arena